Does Hydralazine Cause a Lupus-Like Syndrome?
Yes, hydralazine, a vasodilator used for hypertension and heart failure, causes drug-induced lupus erythematosus (DILE) in 5-10% of patients on long-term high-dose therapy (over 200 mg/day for months to years).[1][2] Symptoms mimic systemic lupus erythematosus (SLE), including joint pain, rash, fever, pleuritis, and fatigue, but typically spare the kidneys and brain unlike idiopathic SLE.[3]
How Common Is Hydralazine-Induced Lupus?
Risk rises with dose and duration: rare below 100 mg/day, but up to 20% in patients on 400 mg/day for years.[1] Slow acetylators (genetic trait affecting 50% of Caucasians, higher in others) face 10-fold higher risk due to prolonged drug exposure.[2][4] It affects women more often, paralleling SLE demographics.[3]
What Symptoms Show Up First?
Arthralgias and myalgias start in 80-90% of cases, followed by rash (50%), fever (20%), and serositis (pleurisy or pericarditis).[1][5] Anti-histone antibodies appear in 95% of cases, confirming DILE; anti-dsDNA is rare, distinguishing it from SLE.[2][3]
How Is It Diagnosed?
Blood tests show elevated ANA (antinuclear antibodies) in nearly all cases, with anti-histone specificity.[3] Diagnosis relies on history of hydralazine use, compatible symptoms, and exclusion of idiopathic SLE. Biopsy, if done, shows lupus-like skin changes.[5]
What Happens If You Stop the Drug?
Symptoms resolve in 50% within weeks and nearly all within 6 months of discontinuation.[1][2] Antibodies may persist years longer but rarely cause ongoing issues.[3]
Can It Turn Into Real Lupus?
No strong evidence links DILE to permanent SLE; it reverses fully in most.[4] Rare persistent cases exist, possibly in those with underlying autoimmune risk.[2]
Who Should Avoid Hydralazine?
Steer clear in SLE patients or family history of lupus, slow acetylators, or those needing long-term high doses. Alternatives like ACE inhibitors or calcium channel blockers carry lower DILE risk.[1][6]
How Does It Compare to Other Drugs Causing Lupus?
Hydralazine tops the list for DILE incidence, ahead of procainamide (20-30% risk), isoniazid, and quinidine.[2][3] Unlike procainamide, hydralazine DILE is milder and less fatal.[5]
[1]: Drug-Induced Lupus Erythematosus - NEJM
[2]: Hydralazine-Induced Lupus - Arthritis Foundation
[3]: Drug-Induced Lupus - UpToDate
[4]: Pharmacogenetics of Hydralazine-Induced Lupus - PubMed
[5]: Clinical Features of Hydralazine Lupus - Rheumatology
[6]: Alternatives to Hydralazine - AHA Guidelines